基于FDA不良事件报告系统的神经乱性恶性综合征的现实世界药监测研究
Yu Zhang1, Wei Deng2, Minjian Wang3
1Department of Hospital Infection Control, Chongqing Mental Health Center, Chongqing, China.
Frontiers in pharmacology
|December 26, 2024
概括
这项研究使用FDA数据确定了与神经乱性恶性综合征 (NMS) 相关的流行药物. 抗精神病药物和抗帕金森症药物最常与NMS风险相关.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 药物不良反应 药物不良反应
背景情况:
- 神经瘤恶性综合征 (NMS) 是一种罕见的,危及生命的药物不良反应.
- 识别与NMS相关的药物对于患者的安全至关重要.
研究的目的:
- 为了确定与NMS风险相关的流行药物.
- 使用FDA不良事件报告系统 (FAERS) 数据库分析NMS风险信号.
主要方法:
- 利用了2004年1月至2024年6月的FAERS数据.
- 采用统计方法,包括ROR,PRR,IC和EBGM用于信号检测.
- 根据性别和年龄组进行了子组分析.
主要成果:
- 确定了10433份与NMS相关的不良事件报告.
- 最受欢迎的药物包括抗精神病药物 (36%),抗帕金森症药物 (20%) 和抗抑郁药 (14%).
- NMS在男性中更为普遍 (54.76%); 儿科NMS病例显示了来自类药物和抗药物的额外风险.
结论:
- 这项药监测研究确定了许多与NMS相关的药物.
- 结果为临床医生提供参考资料,并强调需要进一步进行因果关系研究.
相关概念视频
Pharmacovigilance
732
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
732
Drug Regulation
1.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
180
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
180
Clinical Trials: Overview
2.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.4K
Drug Therapy
26
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
26
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
134
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
134


